ClinConnect ClinConnect Logo
Search / Trial NCT04304456

Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care in Turkey

Launched by SCARE (STUDY GROUP FOR CARBAPENEM RESISTANCE) · Mar 10, 2020

Trial Information

Current as of May 06, 2025

Unknown status

Keywords

Bacteremia Antimicrobial Resistance Mortality Hospital Acquired Infections

ClinConnect Summary

Blood stream infection (BSI) is defined as the identification of a culprit pathogen in the blood culture sample of a participant. As such, and once contaminants are excluded, BSI is the only cause of sepsis where the presence of an infection and the pathogen are known with certainty. This makes BSI the perfect model of infection to study the effects of the micro-organism on the participant, and the effects of the antibiotics and other treatments on survival. There is an increasing trend in antimicrobial resistance rates among microorganisms that are associated with nosocomial infections tre...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \> 18 Years.
  • Hospital Acquired Bloodstream Infection (HA-BSI).
  • Treated in the ICU.
  • ICU acquired OR Hospital acquired prior to ICU admission
  • Exclusion Criteria:
  • Patients that had a positive blood culture in the hospital and transferred to ICU for a different reason than specific treatment of the causes or consequences of HA-BSI.
  • Previous inclusion in the study.
  • HA-BSI is defined as a positive blood culture (BC) sampled after 48 hours following hospital admission.

About Scare (Study Group For Carbapenem Resistance)

Scare (Study Group for Carbapenem Resistance) is a dedicated clinical trial sponsor focused on addressing the critical global health challenge of carbapenem-resistant infections. By facilitating innovative research and fostering collaboration among healthcare professionals, researchers, and institutions, Scare aims to enhance understanding of carbapenem resistance mechanisms and promote the development of effective therapeutic strategies. Through rigorous clinical trials and data-driven insights, Scare is committed to advancing patient care and improving outcomes in the fight against antibiotic-resistant pathogens.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials